Cardiovascular Morbidity and Mortality in Thyroid Cancer Cardiovascular Morbidity and Mortality in Thyroid Cancer
What do we know about the cardiovascular risks of thyroid hormone suppression therapy for thyroid cancer?Clinical Endocrinology
Condition: Thyroid Cancer Interventions: Drug: Thyrogen; Radiation: I-131; Radiation: I-124 Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting
Patients with low-risk thyroid cancers who chose active surveillance have similar worries to those who opt for surgery, but most ultimately express satisfaction with their choice of watchful waiting.Medscape Medical News
What used to be a relatively rare malignancy, thyroid cancer diagnoses are now rising quickly. Dr Leung discusses what we currently know and some of the top questions that remain unanswered.Medscape Diabetes &Endocrinology
3D sonographic measurement of papillary thyroid cancer nodules may be a better method of determining tumor size.Journal of the Endocrine Society
Flossing teeth with Oral-B Glide and similar brands could inadvertently increase exposure to PFAS chemicals, a number of which have been linked to cancer and thyroid disease, a US study indicates.Medscape Medical News
Conclusion: Children with extreme insulin resistance had high prevalence of thyroid nodules, which were not associated with metreleptin treatment. Patients with homozygous INSR mutation had thyromegaly, which may be a novel phenotypic feature of this disease. Further studies are needed to determine the etiology of thyroid abnormalities in patients with extreme insulin resistance. PMID: 30657911 [PubMed - as supplied by publisher]
Introduction to the Theme "New Therapeutic Targets". Annu Rev Pharmacol Toxicol. 2019 Jan 06;59:15-20 Authors: Insel PA, Amara SG, Blaschke TF, Meyer UA Abstract "New Therapeutic Targets" is the theme of articles in the Annual Review of Pharmacology and Toxicology, Volume 59. Reviews in this volume discuss targets for a variety of conditions in need of new therapies, including type 2 diabetes, heart failure with preserved ejection fraction, obesity, thyroid-associated ophthalmopathy, tinnitus, multiple sclerosis, Parkinson's disease and other neurodegenerative diseases, pain, depre...
At-home lab tests are growing in popularity. While many companies focus on specific tests, such as genetic testing or specific screenings, LetsGetChecked, a company with offices in New York, Dublin, and Toronto, hopes to be a central hub that al...
ConclusioniGlarLixi has a safety profile that is consistent with that of its two active components insulin glargine and lixisenatide, with no signals for pancreatitis or thyroid C cell tumors, and no black-box warning for iGlarLixi. There were no unexpected safety findings; iGlarLixi had beneficial effects on glycemic control, with no increased risk of hypoglycemia, despite a greater glycated hemoglobin A1c reduction. In addition, there were also fewer gastrointestinal AEs associated with iGlarLixi compared with lixisenatide alone.FundingSanofi US Inc.
This study explores the prevalence of clonal hematopoiesis related to radioactive iodine exposure and how it impacts overall survival in patients with thyroid cancer.Journal of Clinical Endocrinology &Metabolism